Randomized feasibility trial of the Scleroderma Patient-centered Intervention Network hand exercise program (SPIN-HAND): Study protocol

Abstract

Background:

Significant functional impairment of the hands is nearly universal in systemic sclerosis (SSc, scleroderma). Hand exercises may improve hand function, but developing, testing and disseminating rehabilitation interventions in SSc is challenging. The Scleroderma Patient-centered Intervention Network (SPIN) was established to address this issue and has developed an online hand exercise program to improve hand function for SSc patients (SPIN-HAND). The aim of the proposed feasibility trial is to evaluate the feasibility of conducting a full-scale randomized controlled trial (RCT) of the SPIN-HAND intervention.

Design and methods:

The SPIN-HAND feasibility trial will be conducted via the SPIN Cohort. The SPIN Cohort was developed as a framework for embedded pragmatic trials using the cohort multiple RCT design. In total, 40 English-speaking SPIN Cohort participants with at least mild hand function limitations (Cochin Hand Function Scale ≥3) and an indicated interest in using an online hand-exercise intervention will be randomized with a 1:1 ratio to be offered to use the SPIN-HAND program or usual care for 3 months. The primary aim is to evaluate the trial implementation processes, required resources and management, scientific aspects, and participant acceptability and usage of the SPIN-HAND program.

Discussion:

The SPIN-HAND exercise program is a self-help tool that may improve hand function in patients with SSc. The SPIN-HAND feasibility trial will ensure that trial methodology is robust, feasible, and consistent with trial participant expectations. The results will guide adjustments that need to be implemented before undertaking a full-scale RCT of the SPIN-HAND program.

Trial registration:

ClinicalTrials.gov Identifier: NCT03092024.

Keywords

Feasibility studies Scleroderma Systemic Tele-rehabilitation Trial protocols

Get full access to this article

View all access options for this article.

References

Scleroderma

Seibold J.

. In: Harris

Budd

Firestein

et al , eds. Kelley’s textbook of rheumatology. 7^th ed. Philadelphia, PA: Elsevier 2005; 1279-1308.

Wigley

Hummers

LK.

Clinical features of systemic sclerosis. In: Hochberg

Silman

Smolen

et al ., eds. Rheumatology. Philadelphia: Mosby 2003;1463-1480.

Bassel

Hudson

Taillefer

Schieir

Baron

Thombs

BD.

Frequency and impact of symptoms experienced by patients with systemic sclerosis: results from a Canadian National Survey. Rheumatology (Oxford). 2011;50(4):762-767.

Thombs

van Lankveld

Bassel

et al . Psychological health and well-being in systemic sclerosis: State of the science and consensus research agenda. Arthritis Care Res (Hoboken). 2010;62(8):1181-1189.

Kwakkenbos

Delisle

Fox

et al . Psychosocial aspects of scleroderma. Rheum Dis Clin North Am. 2015;41(3):519-528.

Jewett

Haythornthwaite

Thombs

BD.

Psychosocial issues and care for patients with systemic sclerosis. In: Varga

Denton

Wigley

eds. Scleroderma: from pathogenesis to comprehensive management. New York: Springer 2012;641-648.

Kowal-Bielecka

Landewé

Avouac

et al . EUSTAR Co-Authors. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis. 2009;68(5):620-628.

Kwakkenbos

Jewett

Baron

et al . The Scleroderma Patient-centered Intervention Network (SPIN) Cohort: protocol for a cohort multiple randomised controlled trial (cmRCT) design to support trials of psychosocial and rehabilitation interventions in a rare disease context. BMJ Open. 2013;3(8):e003563.

Kole

Faurisson

. The voice of 12,000 patients: experiences and expectations of rare disease patients on diagnosis and care in Europe. Available from: www.eurordis.org/IMG/pdf/voice_12000_patients/EURORDISCARE_FULLBOOKr.pdf. Accessed September 19, 2017.

10.

Huyard

What, if anything, is specific about having a rare disorder? Patients judgements on being ill and being rare. Health Expect. 2009;12(4):361-370.

11.

Nettleton

Watt

OMalley

Duffey

Understanding the narratives of people who live with medically unexplained illness. Patient Educ Couns. 2005;56(2):205-210.

12.

Reimann

Bend

Dembski

[Patient-centred care in rare diseases. A patient organisations perspective]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2007;50(12):1484-1493.

13.

Kallen

Mayes

Kriseman

de Achaval

Cox

Suarez-Almazor

ME.

The symptom burden index: development and initial findings from use with patients with systemic sclerosis. J Rheumatol. 2010;37(8):1692-1698.

14.

Rannou

Poiraudeau

Berezné

et al . Assessing disability and quality of life in systemic sclerosis: construct validities of the Cochin Hand Function Scale, Health Assessment Questionnaire (HAQ), Systemic Sclerosis HAQ, and Medical Outcomes Study 36-Item Short Form Health Survey. Arthritis Rheum. 2007;57(1):94-102.

15.

Poole

JL.

Musculoskeletal rehabilitation in the person with scleroderma. Curr Opin Rheumatol. 2010;22(2):205-212.

16.

Schouffoer

Ninaber

Beaart-van

Voorde

et al . Randomized comparison of a multidisciplinary team care program with usual care in patients with systemic sclerosis. Arthritis Care Res (Hoboken). 2011;63(6):909-917.

17.

Rannou

Boutron

Mouthon

et al . Personalized physical therapy versus usual care for patients with systemic sclerosis: a randomized controlled trial. Arthritis Care Res (Hoboken). 2017;69(7):1050-1059.

18.

Kraemer

Mintz

Noda

Tinklenberg

Yesavage

JA.

Caution regarding the use of pilot studies to guide power calculations for study proposals. Arch Gen Psychiatry. 2006;63(5):484-489.

19.

Thabane

Chu

et al . A tutorial on pilot studies: the what, why and how. BMC Med Res Methodol. 2010;10(1):1.

20.

Van Teijlingen

Rennie

Hundley

Graham

The importance of conducting and reporting pilot studies: the example of the Scottish Births Survey. J Adv Nurs. 2001;34(3):289-295.

21.

Eldridge

Chan

Campbell

et al . PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. BMJ. 2016;355:i5239.

22.

Relton

Torgerson

OCathain

Nicholl

Rethinking pragmatic randomised controlled trials: introducing the cohort multiple randomised controlled trial design. BMJ. 2010;340(mar19 1):c1066.

23.

van den Hoogen

Khanna

Fransen

et al . 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013;65(11):2737-2747.

24.

Duruöz

Poiraudeau

Fermanian

et al . Development and validation of a rheumatoid hand functional disability scale that assesses functional handicap. J Rheumatol. 1996;23(7):1167-1172.

25.

Roland

Torgerson

DJ.

What are pragmatic trials?

BMJ. 1998;316(7127):285.

26.

Torgerson

CJ.

Designing randomised trials in health, education, and the social sciences: an introduction. Palgrave Macmillan; 2008.

27.

Zwarenstein

Treweek

Gagnier

et al . CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337(nov11 2):a2390.

28.

Lamb

Williamson

Heine

et al . Strengthening and Stretching for Rheumatoid Arthritis of the Hand Trial (SARAH) Trial Team. Exercises to improve function of the rheumatoid hand (SARAH): a randomised controlled trial. Lancet. 2015;385(9966):421-429.

29.

Foster

Taylor

Eldridge

Ramsay

Griffiths

CJ.

Self-management education programmes by lay leaders for people with chronic conditions. Cochrane Database Syst Rev. 2007;(4):CD005108.

30.

Lorig

Holman

Self-management education: history, definition, outcomes, and mechanisms. Ann Behav Med. 2003;26(1):1-7.

31.

Holman

Lorig

. Perceived self-efficacy in self-management of chronic disease. In: Schwarzer

, ed. Self-efficacy: thought control of action. Pennsylvania: Taylor & Francis 1992.

32.

Marks

Allegrante

Lorig

. A review and synthesis of research evidence for self-efficacy-enhancing interventions for reducing chronic disability: implications for health education practice (part I). Health Promot Pract. 2005;6(1):37-43.

33.

Marks

Allegrante

Lorig

34.

Shoemaker

Wolf

Brach

Development of the Patient Education Materials Assessment Tool (PEMAT): a new measure of understandability and actionability for print and audiovisual patient information. Patient Educ Couns. 2014;96(3):395-403.

35.

Poiraudeau

Chevalier

Conrozier

et al . Reliability, validity, and sensitivity to change of the Cochin hand functional disability scale in hand osteoarthritis. Osteoarthritis Cartilage. 2001;9(6):570-577.

36.

Brower

Poole

JL.

Reliability and validity of the Duruoz Hand Index in persons with systemic sclerosis (scleroderma). Arthritis Rheum. 2004;51(5):805-809.

37.

Hinchcliff

Beaumont

Thavarajah

et al . Validity of two new patient-reported outcome measures in systemic sclerosis: patient-reported outcomes measurement information system 29-item Health Profile and Functional Assessment of Chronic Illness Therapy-Dyspnea short form. Arthritis Care Res (Hoboken). 2011;63(11):1620-1628.

38.

Kwakkenbos

Thombs

Khanna

et al . Performance of the patient-reported outcomes measurement information system-29 in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort Study. Rheumatology (Oxford). 2017; 56(8):1302-1311.

39.

Rabin

de Charro

EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33(5):337-343.

40.

Julious

SA.

Sample size of 12 per group rule of thumb for a pilot study. Pharm Stat. 2005;4(4):287-291.

41.

Sim

Lewis

The size of a pilot study for a clinical trial should be calculated in relation to considerations of precision and efficiency. J Clin Epidemiol. 2012;65(3):301-308.